Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three referees whose comments to the authors are shown below. As you will see while referee 3 is considerably more critical the other two referees are more positive and would support publication here after adequate, but substantial revision. On balance I have come to the conclusion that we should be able to consider a revised version of this manuscript in which you need to address the referees' criticisms in an adequate manner. However, it will be indispensable to develop the study further mechanistically along the lines suggested by referee 1 and to address the concerns referee 3 raises on the conclusiveness of the data.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript as well as on the final assessment by the referees.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor The EMBO Journal ------------------------------------------------REFEREE COMMENTS
Referee #1 (Remarks to the Author):
The ms by Granata et al provides evidence for a role of the COP9 signalosome in controlling the stability of SV proteins via interaction with TorsinA.
The authors identify a novel interaction of TorsinA with the COP9 subunit CSN4 and show that both TorsinA and CSN4 levels affect the expression levels of Snapin and Stonin2 . Overexpression of the dystonia causing mutant form of TorsinA also reduces a Stonin2 cellular level that affects endocytosis of Syt1. This defect can be rescued by overexpression of Stonin2.
General:
1. The finding of the novel interaction of TorsinA with the Cop9 signalosome is interesting and the biochemical data solid. However, some of the claims appear to be a bit too strong e.g. the authors claim that TorsinA directly modulates CSN4's proteolytic activity, but I did not see any evidence of this claim? Similarly, "suggesting that COP9 activity controls snapin stability via a TA-dependent mechanism." Why? The authors only show that TorA and CSN4 KD have the same effect on snapin levels but do not show that CSN4 activity depends on TorA presence. The authors should show that CSN4 activity depends on TorA presence.
2. Figure 2c : The authors state that "CSN4 and TA antibodies showed a partial co-localisation of both proteins on discrete puncta along neurites, which are reminiscent of synaptic boutons in primary neurons". Why do the authors only show neuronal staining in the suppl. Figure? I would love to see a more thorough co-localization study in primary neurons. In my opinion, the impact of the paper would significantly increase if the authors use primary neurons instead of neuroblastoma cells for Figures 2 and also Fig 8. 3. Figure 3A : by eye-balling the figure it appears that both CSN4 siRNA and curcumin affect TA levels, did the authors perform a more quantitative analysis to exclude that is the case? To me this appears to be a plausible mechanism.
4. Figure 6 shows that Stonin2 is neddylated and that this neddylation increases when ΔE-TA is overexpressed. To link this observation with COP9 activity (as the authors claim in the heading), the authors should show similar increase upon siRNA KD of CSN4.
5. Fig. 7 shows that cellular levels of snapin are reduced upon PKD inhibition, this is in line with the curcumin treatment and thus supports the conclusion that the COP9 complex may be involved but does not exclude alternative mechanisms, could the authors show that snapin-Ub levels are increased or that MG132 treatment prevents PKD inhibition dependent snapin reduction? 6. The manuscript is on the interaction between TorsinA (TA) and the COP9 signalosome (CSN). TA belongs to the AAA+ superfamily of ATPases. DYT1 dystonia is a genetic disease caused by deletion of a glutamate residue (dE) in the TA protein in most affected individuals. It is a severe movement disorder characterized by dystonic muscle contractions causing abnormal posturing. The mechanism on how dE TA mutant causes the disease is still not known. TA has been shown to affect the dopamine turnover by modulation of the plasma membrane delivery of the dopamine transporter DAT-1.
The authors identified CSN4 as a TA-interacting protein using a yeast two-hybrid screen. The interaction also was confirmed by GST-pulldown assays. Snapin, a synaptic regulator that has been shown to bind to TA was not competing with binding of CSN4 indicating an independent binding site. GST-pulldowns demonstrated that the dE mutant of TA does not bind to CSN4 anymore but still binds to snapin. This observation was confirmed also by immunoprecipitation of endogenous proteins. CSN4 partially co-localizes with synaptic vesicle markers as shown in immunostaining experiments.
Interestingly, siCSN4 and incubation with curcumin did not change TA protein levels in SH-SY5Y cells but led to a reduction of snapin levels. Moreover, siRNA directed against TA had the same destabilizing effect on snapin, which was rescued using the proteasome inhibitor MG132. Since snapin was degraded in a CSN mediated and proteasome-dependent manner the authors looked for additional synaptic proteins that could be affected by knockdown of TA or CSN4. In this screen stonin 2 was identified to be affected by TA and the CSN downregulation. By coimmunoprecipitations stonin 2 was shown to bind to TA but not the dE TA mutant.
To see whether neddylation is involved endogenous NEDD8 was immunoprecipitated and precipitated proteins were analyzed by western blotting. Using a stonin 2 antibody a number of bands were identified. The authors conclude that stonin 2 was neddylated. Since downregulation of CSN4 reduced stonin 2 protein levels and most likely CSN-mediated deneddylation, neddylation seems to be necessary for stonin 2 degradation. Snapin was not detected in the Nedd8-IPs suggesting a different mechanism of protein stabilization. To test the hypothesis that snapin is stabilized by CSN-mediated phosphorylation inhibitors against PKD and CKII were used. The PKD inhibitor significantly reduced snapin levels. Moreover, in vitro PKD phosphorylates snapin.
In former studies the authors showed that TA regulates synaptic vesicle trafficking characterized by accumulation of Syt1 on the surface. Syt1 has been show to be mainly affected by stonin 2. Because dE TA mutant expression leads to destabilization of stoning 2 they questioned whether the defect in Syt1 recycling could be rescued by stonin 2 overexpression. In fact, they could show that stonin 2 overexpression rescued this effect.
Comments:
-The authors should use the common nomenclature for the protein complex called the COP9 signalosome or CSN. Using Cop9 is confusing and not in agreement with the current literature.
-The authors showed that snapin is degraded by the proteasome. They should show it for stonin 2 as well.
-The modification of stonin 2 by neddylation shown in Fig. 6A is not clear. The authors performed pulldowns with a Nedd8 antibody and detected multiple bands stained by the stonin 2 antibody. These bands resemble modifications by poly-ubiquitination or by phosphorylation. The authors should clearly show (perhaps by mass spectrometry) that the bands contain Nedd8. This is important because in the same precipitates the authors detected CUL-1, the neddylated component of the cullin-RING ubiquitin ligase, which might ubiquitinate stonin 2. In other words, the Nedd8 antibody might precipitate the neddylated CUL1, which is associated with the ubiquitin ligase and the substrate stonin 2.
-In vitro PKD phosphorylates snapin. The authors propose that the mechanism of protein stabilization for snapin and stonin 2 are different in this point. They should use stonin 2 as a negative control in the in vitro phosphorylation assay.
-Obviously the CSN and TA act in the same degradation pathway. However, what is the function of TA? There is only little speculation on TA function in the discussion. Isn't it possible that TA and the CSN are both components of a complex that ubiquitinates snapin as well as stonin 2 and perhaps additional substrates?
Referee #3 (Remarks to the Author):
After reading this study it seems that the model presented by Granata et al. is as follows: overexpression of dE-TA leads to disruption of the Cop9-TA complex resulting in increased neddylation of stonin 2 which in turn results in accumulation of nedd-stonin in perinuclear bodies and subsequent degradation; this results in an overall decrease in stonin in the cytoplasm. There are some interesting findings here, but a number of issues must be addressed:
The authors found that CSN4 binds to deltaE-TA in Fig.1A , but does not bind in Fig.2A -this seems a direct contradiction. What is the explanation? Also, why does the mutation near the C-terminus of TA have no effect on binding to CSN4 in the context of full length TA but completely disrupts binding of deltaE6 -why is this? 2. Fig.5B . Interestingly, overexpression of deltaE-TA can reduce the level of stonin-2 level. The authors suggest that CSN4, TA and stonin-2 form a complex to stabilize stonin-2. They also claimed that deltaE-TA does not bind to either CSN4 or stonin-2 but that delta-TA can drive mistargeting of endogenous TA, resulting in destablization of the complex. This seems to be highly spectulative: can the authors determine whether deltaE-TA can in fact bind to native TA? 3. The authors indicate that snapin is not involved in DYT1 dystonia, because snapin can bind deltaE-TA as well as wt-TA. In my view, this result might suggest that deltaE-TA is a dominant negative form of TA for snapin. To test this, the authors should consider experiments to see whether overexpression of deltaE-TA reduces the levels of snapin. 4. Fig.8M . The authors found that plasma membrane stranded Syt1 is reduced by overexpression of EGFP-STN2 plus deltaE-TA. However, the data in this panel suggest defects in exocytosis itself; is exocytosis perturbed in these experiments? Without this information, this figure cannot be interpreted. Also in Fig. 8 , the authors hould have compared total syt1 level between control and the dE-TA sample. Again, dE-TA seems to impair exocytosis regardless of stonin 2. Actually, the way that the assay that was used (luminal domain Ab uptake) was suitable for testing exocytosis but not endocytosis, as follows: the authors added high K+ solution containing the Syt1 Ab directly do the cell. This will depolarize the neuron and cause exposure of the luminal domain to the syt1 Ab. The Ab binds to the syt1 luminal domain. From this point on, some vesicles will get endocytosed while others will not. But there is no way of telling which is which, unless you wash the cell and quantify the surface fraction (leave cells unpermeabilized, stain with Alexa-labelled secondary Ab) and the total fraction (permeabilize the cell, then stain with Alexa-secondary Ab) differentially. The authors didn't do this; rather, they just labeled all exocytosed vesicles and permeabilized the cell membrane. This is more analogous to bafilomycin experiments in pHluorin imaging studies, and results in labeling all the 'first-fusion' vesicles. 5. Fig.5D . For CSN4 siRNA group, it seemed a bit strange that the amount of stonin that was precipitated was not diminished at all; can the authors explain this? 6. Fig 6B (d~f) . It is unclear if they claim dE-TA can drag the 'Nedd-Stonin2' to the perinuclear body, or whether the dE-TA and Nedd-stonin2 both happened to end up in perinuclear bodies by coincidence. Also, it is worthwhile to do triple immunostaining of dE-TA, Nedd8 and Stonin2 in the same sample in order to test if the accumulation of Nedd has anything to do with reduction of stonin 2. Fig 6B, wild-type overexpressing samples are missing. Looking at Fig 6A, there is significant fraction of Nedd-stonin even in the wt overexpressor. So, the signal in 6B(e) might not be real. Another odd thing in 6A is that the overall amount of Neddylation did NOT seem to change much, but the pattern of Neddylation changed. The top band showed a reduction in dE expressing cells while the middle and bottom bands got mildly stronger. The comments of the reviewers are addressed in detail below:
Again in
Review 1:
Some of the claims appear to be a bit too strong e.g. the authors claim that TorsinA directly modulates CSN4's proteolytic activity.
We have reworded the text suggesting that both torsinA and CSN work together to regulate the stability of a subset of synaptic vesicle proteins.
I would love to see a more thorough co-localization study between torsinA and CSN4 in primary neurons.
We fully agree that further co-localisation data between torsinA and CSN4 would strengthen the paper. We have therefore added a new co-localisation analysis of torsinA and CSN4 in primary cerebellar granule neurons ( Figure 2D ), which complement similar data obtained in primary hippocampal neurons (Supplemental Figure 1G -L) and human neuroblastoma cells ( Figure 2C and Supplemental Figure 1A -F).
Both CSN4 siRNA and curcumin affect TA levels, did the authors perform a more quantitative analysis to exclude that is the case?
Following the suggestion of this reviewer, quantitative analysis was performed, which confirmed that TorsinA was not significantly affected by CSN4 downregulation (Supplemental Figure 3) .
Stonin 2 is neddylated and that this neddylation increases when DE-TA is overexpressed. The authors should show similar increase upon siRNA KD of CSN4.
The requested data is shown in Figure 5D and confirms that CSN4 downregulation does increase neddylation of stonin 2. To facilitate the detection of neddylated protein and prevent their degradation, the experiment was performed in the presence of the proteasome inhibitor lactacystin.
The authors should show that snapin-Ub levels are increased or that MG132 treatment prevents PKD inhibition dependent snapin reduction.
We have performed the requested experiment as shown in Figure 6B . MG132 and lactacystin gave comparable results for both snapin (data not shown) and stonin 2 ( Figure 4A and 5D ). Fig. 8 (Fig. 7) : Authors should show that CSN4 and TA siRNA have similar phenotypes.
Our previous paper showed similarity between ΔE-TA and wt-TA knockdown phenotypes (Granata et al 2008) . As a result, in the present study we did not re-investigate the effect of TA downregulation on Syt1 recycling. In addition, since CSN is involved into a wide range of biological activities, it is likely that we would see a more complex phenotype by downregulating CSN4 compared with TA.
Does CSN4 localization depend on TorA?
TA downregulation experiments clearly demonstrate that CSN4 localisation does not depend on TA.
We apologise for the omission in the original version of the paper, which has now been amended (page 7).
Does CSN4 siRNA affect levels of AP-2 or Eps15?
We are very thankful to the reviewer for this comment, since it prompted us to investigate the effects of CSN inhibition on AP2. As shown in Figure 4A , we found that AP2 is also a potential target of the CSN-mediated pathway. Our analysis showed that AP2 is downregulated in cells upon treatment with siRNAs against TA and CSN4. Strikingly, however, ΔE-TA expression did not have any effect on AP2 levels, as seen in the case of snapin. This result strengthens our original hypothesis that TA regulates multiple synaptic proteins involved in exo/endocytosis.
Figure 4: does curcumin affect steady state levels of stonin2?
Curcumin does not affect stonin 2 levels as stated in the text on page 12.
Reviewer 2:
The authors should use the common nomenclature for the protein complex called the COP9 COP9 signalosome is commonly abbreviated as CSN. Following the suggestion of this reviewer, we used this abbreviation throughout the manuscript.
Snapin is degraded by the proteasome. They should show it for stonin 2 as well.
In this amended manuscript, we show that stonin 2 degradation is inhibited by the proteasomal inhibitors MG132 and lactacystin ( Figures 4A and 5D ). Fig. 6A is not clear.
The modification of stonin 2 by neddylation shown in
To clarify this point, we now show in Figure 5D that the multiple bands identified by stonin 2 antibody, are also stained for NEDD8 and poly-ubiquitin, indicating that stonin 2 is both neddylated and poly-ubiquitinylated.
In vitro PKD phosphorylates snapin. The authors propose that the mechanism of protein stabilization for snapin and stonin 2 are different in this point.
Further to the reviewers comment, we performed additional experiments and found that stonin 2 also appears to be phosphorylated by PKD in vitro ( Figure 6A ). However, the regulation of snapin stability seems to diverge from stonin 2, because snapin stability is specifically affected by PKD inhibition and curcumin treatment ( Figures 3A, 3D, 6B ), whilst that of stonin 2 is not ( Figure 6B ).
Isn't it possible that TA and the CSN are both components of a complex that ubiquitinates snapin as well as stonin 2 and perhaps additional substrates?
Further investigation has shown that also AP2 levels are affected by torsinA and CSN4 knockdown ( Figure 4A ), and that stonin 2 is also poly-ubiquitinated upon CSN4 downregulation or ΔE-TA expression. This result strongly suggests that both TA and CSN4 are part of the same pathway, which target specific synaptic proteins for degradation. We have speculated that TA may regulate the stability of target proteins by behaving as a chaperone, regulating their correct folding (page 17-18).
Reviewer 3: 1) Fig. 1 & 2 . The authors found that CSN4 binds to deltaE-TA in Fig.1A , but does not bind in Fig. 
2A -this seems a direct contradiction. What is the explanation?
The data presented are consistent findings obtained in many independent experiments and so a real phenomenon. The differences observed between co-immunoprecipitation from cell lysates and pulldown assays or two-hybrid screen may due to the nature of the tag used in these experiments (HA vs GFP, GST or Gal4-BD), which could affect the conformation of the recombinant proteins and/or their ability to assemble in functional oligomers. The expression system (E. coli for GST-TA, S. cerevisiae for TA-Gal4-BD or mammalian cells for HA-TA and GFP-TA) may also contribute to these discrepancies. However, both the HA and GFP tags allow the assembly of oligomeric complexes in mammalian cells (Supplemental Figure 9) , thus suggesting that the results obtained with HA-TA and GFP-TA in SH-SY5Y cells and mammalian neurons (Figure 2A onwards) closely match the physiological behaviour of wt-TA and ΔE-TA.
Also, why does the mutation near the C-terminus of TA have no effect on binding to CSN4 in the context of full length TA but completely disrupts binding of deltaE6 -why is this?
The lack of interaction between CSN4 and GST-ΔE6 fragment may be due to the combination of the ΔE mutation and the lack of the ATP-binding domain, which could affect TA conformation. See also point 1.
2) This seems to be highly speculative: can the authors determine whether deltaE-TA can in fact bind to native TA?
New data shown in Supplementary Figure 9 indeed demonstrate that wt-TA and ΔE-TA coimmunoprecipitate.
3) To test this, the authors should consider experiments to see whether overexpression of deltaE-TA reduces the levels of snapin.
We had previously observed (Granata et al., 2008 ) that levels of snapin are not affected by ΔE-TA. The text has been amended accordingly on page 8.
4) However, the data in this panel suggest defects in exocytosis itself; is exocytosis perturbed in these experiments?
Additional experiments performed in primary hippocampal neurons using SytpHluorin as a reporter showed that endocytosis but not exocytosis is affected by ΔE-TA overexpression ( Figure 7O ,P). To clarify this point, we performed additional experiments using SytpHluorin in SH-SY5Y to distinguish between vesicular and surface pools of Syt1. The outcome showed defective retrieval of Syt1 from the plasma membrane upon stimulation ( Figure 7N and Supplemental Figure 8 ). Also the total amount of endogenous Syt1 pre and post-stimulation is not altered by the expression of ΔE-TA with or without EGFP-stonin 2 (Supplemental Figure 7) .
5) For CSN4 siRNA group, it seemed a bit strange that the amount of stonin that was precipitated was not diminished at all; can the authors explain this?
This is an important point and the quality of the gel originally submitted was suboptimal for which we apologise. We have now included a clearer blot ( Figure 5C ), which shows reduced levels of stonin 2 upon CSN4 knockdown.
6) Also, it is worthwhile to do triple immunostaining of dE-TA, Nedd8 and Stonin2 in the same sample in order to test if the accumulation of Nedd has anything to do with reduction of stonin 2.
To address this point and overcome the issue that both antibodies against NEDD8 and stonin 2 were raised in the same species, we transfected SH-SY5Y cells with EGFP-stonin 2. Immunofluorescence analysis demonstrate that ΔE-TA, NEDD8 and stonin 2 accumulate in the membranous whorls in cells overexpressing ΔE-TA ( Figure 5E ) Fig 6B, This issue has been addressed by quantifying the total amount of neddylated stonin 2. No significant difference between control and wt-TA overexpressed cells was seen (Supplemental Figure 5B) . Immunofluorescence analysis also proved that NEDD8 distribution and total levels are unchanged in wt-TA overexpressing cells (Supplemental Figure 6C) .
Again in
We hope that these changes made to the text and figures have allowed us to assemble a much improved, stronger manuscript, which would appeal to the broad readership of EMBO Journal.
2nd Editorial Decision 19 October 2010
Thank you for sending us your revised manuscript. Our original referee 1 has now seen it again, and you will be pleased to learn that in his/her view you have addressed all criticisms in a satisfactory manner. The paper will now be publishable in The EMBO Journal and you will receive a formal acceptance letter shortly.
Thank you very much again for considering our journal for publication of your work.
Yours sincerely,
Editor
The EMBO Journal
------------------------------------------------REFEREE COMMENTS
I carefully read the rebuttal by Granata et al. and come to the conclusion that they addressed all concerns/comments to my satisfaction and added a substantial amount of new data that strengthened the manuscript. As I see it now, TorsinA and CSN4 both regulate the levels of the synaptic proteins Snapin, AP2 and Stonin2 (and most likely more, not tested, proteins). The claim that "CSN activity controls snapin stability via a TA-dependent mechanism" has been withdrawn/reworded to state that they both regulate the stability of a set of synaptic proteins, which I can accept.
Concerning the answers to referee 3's comments:
1 the discrepancy between in vitro GST pulldown and IP from cell lysate: the author's reply that the different tags might interfere with binding is plausible. Alternative explanation may be that in mammalian cells other complexes may compete for binding with CSN4 and that the deltaE mutant has lower affinity. I agree with the authors that results in mammalian cells closely match the physiological behavior.
2 convincing 3 OK 4 Fig 7O,P are not the most convincing data in the manuscript, are they meant to show that exocytosis is not affected? 7O shows a small effect p<0.06 (?) on endocytosis and 7P a small effect on exocytosis p<0.04. In my opinion, the combination of both effects may explain the accumulation of SytI at the cell surface.
